| Largest shareholders, September 30, 2026 | Number of shares | Capital (%) |
|---|---|---|
| Crafoord family and the Crafoord Foundation | 26.074.939 | 16.6 |
| Segulah Venture AB, Segulah AB, Segulah Medical Acceleration AB | 15.870.271 | 10.1 |
| Fredrik Rapp | 11.879.088 | 7.6 |
| Avanza Pension | 9.002.885 | 5.7 |
| Fjärde AP-fonden | 8.187.000 | 5.2 |
| Unionen | 6.080.000 | 3.9 |
| Nordnet Pensionsförsäkring | 5.123.063 | 3.3 |
| CBNY-National Financial Services | 4.792.815 | 3.0 |
| Swedbank Robur Microcap | 4.607.500 | 2.9 |
| Futur Pension | 3.427.000 | 2.2 |
| TIN NY Teknik | 383.963 | 0.2 |
| JP Morgan | 245.037 | 0.2 |
| Others | 61.925.448 | 39.4 |
| Total | 157,215,046 | 100.0 |
Ownership structure
Backed by evidence and guidelines
Neuromuscular monitoring is now a clinical and operational necessity, driven by guidelines and the high incidence of residual neuromuscular block without objective monitoring.
TOF Monitoring: Complete Buying Guide
Key differences between qualitative and quantitative TOF monitoring, the five criteria for evaluating TOF devices, and comparisons of leading solutions.
Empower your practice
Senzime is here to support you in empowering your practice. Start today by reading a blog, watching a video or a webinar.
About Senzime
A leading medical device company with a mission to safeguard every patient's journey, from anesthesia to recovery.
A leading global medical device company
Senzime is listed on Nasdaq Main Market (SEZI) and cross traded in the US on the OTCQX list (SNZZF).